Takara Bio has announced on April 9 that two gene therapeutic agents for T cell therapy, NY-ESO-1 · siTCRTM, and NY-ESO- (TBI-1301, TBI-1301-A), and a CART cell product, CD 19 · CAR (TBI-1501), a chimeric antigen receptor transgenic T cell (CART) therapy targeting CD 19, jointly developed by both companies, will be exclusively sold by Otsuka Pharmaceutical.
Takara Bio news release, April 9, 2018
Takara Bio licenses TCR and CART therapy products out to Otsuka Pharma